Devices and methods for facilitating and controlling use of a medication
View Patent ↗A method for providing a drug includes providing an inactive form of a drug. The method also includes chemically converting the inactive form of the drug to an active form to provide a drug formulation usable by a patient in need thereof, including using a device configured to remove an abuse-preventing additive from the inactive form of the drug. The method also includes dispensing the drug formulation to the patient in need thereof.
1. A method, comprising:
(a) adding an inactive, non-absorbable form of gamma hydroxybutyrate (GHB) to an in-home device, wherein the inactive, non-absorbable form of GHB is a n-polyol (C4 or greater) ester of GHB;
(b) chemically converting, using the device, the inactive, non-absorbable form of GHB in step (a) to an active form of GHB to provide a GHB formulation usable by a patient in need thereof, including passing the inactive, non-absorbable form of GHB through a filter or packed bed of the device containing a catalyst or reagent to generate the active, absorbable form of GHB; and
(c) dispensing the GHB formulation of step (b) from the device to the patient for use by the patient in need thereof.
2. The method of claim 1 , further comprising treating the patient via ingestion of the drug GHB formulation of step (c) by the patient.
3. The method of claim 1 , wherein the dispensing of step (c) includes dispensing a single dose of the active, absorbable form of the drug GHB to the patient.
4. A method, comprising:
(a) providing an inactive, non-absorbable form of gamma hydroxybutyrate (GHB) to a patient in need thereof, wherein the inactive, non-absorbable form of GHB is a n-polyol (C4 or greater) ester of GHB;
(b) chemically converting the inactive, non-absorbable form of GHB in step (a) to an active form of GHB, including passing the inactive form of GHB through a filter, or packed bed of an in-home device containing a catalyst or reagent to generate the active, absorbable form of GHB, the filter including activated carbon elements; and
(c) dispensing the active, absorbable form of GHB of step (b) to the patient.
5. The method of claim 4 , further comprising treating the patient via ingestion of the GHB of step (c) by the patient.
6. The method of claim 4 , wherein the providing of step (a) includes providing a single dose of the inactive, non-absorbable form of GHB.
7. The method of claim 4 , wherein the inactive, non-absorbable form of GHB is a prodrug or precursor compound for GHB.
8. The method of claim 4 , wherein the device includes one or more of the following: security features that restrict access to the device, a lockout feature, a remote connection to a wireless device, manual override of control features, an alarm, and a balance.
9. The method of claim 8 , further comprising adjusting parameters associated with a dose of the active, absorbable form of GHB dispensed at step (b) based on communication between a prescriber and the device.
10. The method of claim 1 , wherein the device includes one or more of the following: security features that restrict access to the device, a lockout feature, a remote connection to a wireless device, manual override of control features, an alarm, and a balance.
11. The method of claim 10 , further comprising adjusting parameters associated with a dose of the active, absorbable form of the drug GHB dispensed at step (c) based on communication between a prescriber and the device.